Our Pricing

Wegovy or Mounjaro Better for Weight Loss Results?

Published on: June 03, 2026

If you're wondering whether Wegovy or Mounjaro is better for weight loss, you're not alone—this is one of the most common questions UK patients ask when considering prescription weight loss injections. Both medications are MHRA-licensed GLP-1 receptor agonists proven to deliver significant weight reduction, but they work through different mechanisms and produce varying results in clinical trials. At Cured Pharmacy, our UK-registered clinical team helps you understand which treatment may suit your individual health profile, with transparent pricing from £135.00 for Wegovy and competitive rates for Mounjaro.

How Mounjaro and Wegovy Work Differently

Mounjaro contains tirzepatide, the UK's first dual GIP/GLP-1 receptor agonist, meaning it activates two separate hormone pathways that regulate appetite and blood glucose [1]. This dual action distinguishes it from Wegovy, which contains semaglutide—a GLP-1 receptor agonist that works through a single pathway. Both medications slow gastric emptying, reduce hunger signals, and improve insulin sensitivity, but tirzepatide's additional GIP receptor activation may produce enhanced metabolic effects.

Wegovy has been available in the UK since 2023 and is administered as a once-weekly subcutaneous injection, with doses escalating from 0.25mg to a maintenance dose of 2.4mg [2]. Mounjaro follows a similar weekly injection schedule but offers higher maximum doses—up to 15mg—which may be prescribed based on individual response and tolerability. Both treatments require ongoing clinical supervision by a UK prescriber, and neither is suitable for cosmetic weight loss in individuals with a BMI below 30 (or 27 with weight-related comorbidities).

Clinical Trial Results: Wegovy or Mounjaro Better for Weight Loss?

Head-to-head clinical data provides the clearest answer to whether Wegovy or Mounjaro delivers superior weight loss outcomes. In the SURMOUNT-1 trial, participants taking the highest dose of Mounjaro (15mg tirzepatide) achieved an average weight reduction of 22.5% over 72 weeks—one of the highest percentages ever recorded in obesity pharmacotherapy [1]. By comparison, the STEP 1 trial showed Wegovy (2.4mg semaglutide) produced an average weight loss of 14.9% over 68 weeks [2].

It's important to note that individual results vary significantly based on adherence, baseline BMI, lifestyle modifications, and metabolic factors. Some patients respond exceptionally well to semaglutide and experience fewer side effects, while others achieve better outcomes with tirzepatide's dual-action mechanism. Your UK prescriber will consider your medical history, previous treatment responses, and current medications when recommending the most appropriate option.

Real-World Effectiveness in UK Patients

Beyond controlled trial environments, real-world evidence from UK prescribing data suggests both medications deliver meaningful weight reduction when combined with dietary changes and increased physical activity. Patients typically notice reduced appetite within the first week of treatment, with progressive weight loss becoming evident over 12–16 weeks. Maximum weight reduction generally occurs between 60–72 weeks, after which weight stabilisation is the therapeutic goal [3].

Side Effects: What to Expect from Each Treatment

Both Mounjaro and Wegovy share a similar side effect profile, predominantly affecting the gastrointestinal system. The most commonly reported adverse effects include nausea, diarrhoea, constipation, abdominal discomfort, and occasional vomiting—particularly during dose escalation phases [1][2]. These symptoms are generally mild to moderate and tend to diminish as your body adapts to the medication over 4–8 weeks.

Clinical trial data indicates that nausea occurs in approximately 44% of Mounjaro users and 40% of Wegovy users, though severe cases requiring treatment discontinuation remain uncommon [1][2]. Starting at the lowest dose and following the prescribed titration schedule significantly reduces the likelihood of intolerable side effects. Rare but serious risks include pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies but not conclusively demonstrated in humans). Both medications carry a black box warning regarding thyroid tumours and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Managing Common Side Effects

UK prescribers typically recommend eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated to minimise gastrointestinal discomfort. If nausea persists beyond the first month or becomes severe, your prescriber may adjust your dose escalation schedule or consider switching to an alternative treatment. Never increase your dose faster than the prescribed schedule, as this significantly increases the risk of adverse effects.

Cost Comparison: Mounjaro vs Wegovy UK Pricing

Pricing is a significant consideration for UK patients, as neither Mounjaro nor Wegovy is currently funded by the NHS for routine weight management (though availability may vary by local Integrated Care Board). At Cured Pharmacy, Wegovy is available from £124.99 representing one of the most competitive rates in the UK private market. Mounjaro pricing reflects its status as a newer dual-action therapy, with costs varying based on prescribed dose strength.

When comparing total treatment costs, consider that weight loss medications are typically prescribed for 12–24 months to achieve and maintain optimal results. Your UK prescriber will determine the minimum effective dose for your individual circumstances, which directly impacts monthly expenditure. Cured Pharmacy offers transparent upfront pricing with no hidden consultation fees—your prescription cost is clearly displayed before you complete your clinical assessment.

Wegovy or Mounjaro: Which Should You Choose?

The decision between Wegovy and Mounjaro depends on multiple clinical factors that your UK prescriber will assess during your consultation. Mounjaro may be more suitable if you require higher efficacy based on trial data, have previously tried semaglutide-based treatments with suboptimal results, or have specific metabolic profiles that may benefit from dual GIP/GLP-1 activation [1]. Wegovy remains an excellent first-line option for many patients, particularly those seeking a well-established treatment with extensive real-world safety data and lower initial costs.

Neither medication is inherently 'better'—the optimal choice is the one that aligns with your medical history, treatment goals, budget, and tolerability profile. Some patients may start with Wegovy due to its lower price point and switch to Mounjaro if weight loss plateaus, while others may begin with Mounjaro based on their prescriber's clinical judgement. Both treatments require commitment to lifestyle modifications including reduced calorie intake and regular physical activity to achieve the results demonstrated in clinical trials [2][3].

Who Should Not Use These Medications

Both Wegovy and Mounjaro are contraindicated in pregnancy, breastfeeding, patients under 18 years, and individuals with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. They should be used with caution in patients with diabetic retinopathy, severe gastrointestinal disease, or a history of pancreatitis. Your UK prescriber will conduct a thorough medical assessment to ensure either medication is safe and appropriate for your individual circumstances.

How to Start Treatment at Cured Pharmacy

Beginning your weight loss journey with Mounjaro or Wegovy at Cured Pharmacy starts with a free online consultation that takes under three minutes to complete. You'll answer questions about your medical history, current medications, weight loss goals, and any previous treatments you've tried. Our UK-registered prescribers review every assessment individually—there are no automated approvals—and will only issue a prescription if the medication is clinically appropriate and safe for you.

If approved, your medication is dispensed by our GPhC-registered pharmacy (registration number 9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073) and delivered in 100% discreet packaging directly to your UK address. You'll receive clear instructions on injection technique, dose escalation schedules, and how to store your medication properly. Ongoing clinical support is available by phone on (+44) 116 4646009 should you have questions or concerns during your treatment.

All prescription weight loss medications available at Cured Pharmacy—including Mounjaro, Wegovy, and Saxenda—are genuine UK-licensed products sourced through regulated supply chains. We never supply unlicensed or compounded alternatives, ensuring you receive the same quality medication available through high-street pharmacies, with the added convenience of online ordering and home delivery.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss medications are most effective when combined with reduced calorie intake and increased physical activity.